Telix Pharmaceuticals Limited Price Chart
Telix Pharmaceuticals Limited TLX.XA Financial and Trading Overview
| Telix Pharmaceuticals Limited stock price | 14.83 AUD |
| Previous Close | 10.85 AUD |
| Open | 10.94 AUD |
| Bid | 0 AUD x N/A |
| Ask | 0 AUD x N/A |
| Day's Range | 10.86 - 11.45 AUD |
| 52 Week Range | 3.82 - 12.05 AUD |
| Volume | 128.61K AUD |
| Avg. Volume | 207.66K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 2.317624 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.285 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TLX.XA Valuation Measures
| Enterprise Value | 3.33B AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 45.064034 |
| Enterprise Value/Revenue | 20.792 |
| Enterprise Value/EBITDA | -48.481 |
Trading Information
Telix Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 2.317624 |
| 52-Week Change | 168.44% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.05 AUD |
| 52 Week Low | 3.82 AUD |
| 50-Day Moving Average | 10.08 AUD |
| 200-Day Moving Average | 7.44 AUD |
TLX.XA Share Statistics
| Avg. Volume (3 month) | 207.66K AUD |
| Avg. Daily Volume (10-Days) | 179.04K AUD |
| Shares Outstanding | N/A |
| Float | 246.32M |
| Short Ratio | N/A |
| % Held by Insiders | 27.58% |
| % Held by Institutions | 13.25% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -65.010% |
| Operating Margin (ttm) | -45.71% |
| Gross Margin | 61.55% |
| EBITDA Margin | -42.88% |
Management Effectiveness
| Return on Assets (ttm) | -25.050% |
| Return on Equity (ttm) | -253.34% |
Income Statement
| Revenue (ttm) | 160.1M AUD |
| Revenue Per Share (ttm) | 0.52 AUD |
| Quarterly Revenue Growth (yoy) | 2803.30% |
| Gross Profit (ttm) | 98.54M AUD |
| EBITDA | -68662000 AUD |
| Net Income Avi to Common (ttm) | -104079000 AUD |
| Diluted EPS (ttm) | -0.285 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 116.33M AUD |
| Total Cash Per Share (mrq) | 0.37 AUD |
| Total Debt (mrq) | 10.45M AUD |
| Total Debt/Equity (mrq) | 13.06 AUD |
| Current Ratio (mrq) | 2.025 |
| Book Value Per Share (mrq) | 0.253 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -63970000 AUD |
| Levered Free Cash Flow (ttm) | -30140376 AUD |
Profile of Telix Pharmaceuticals Limited
| Country | Australia |
| State | VIC |
| City | North Melbourne |
| Address | 55 Flemington Road |
| ZIP | 3051 |
| Phone | 61 3 3093 3897 |
| Website | https://telixpharma.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 234 |
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Q&A For Telix Pharmaceuticals Limited Stock
What is a current TLX.XA stock price?
Telix Pharmaceuticals Limited TLX.XA stock price today per share is 14.83 AUD.
How to purchase Telix Pharmaceuticals Limited stock?
You can buy TLX.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Telix Pharmaceuticals Limited?
The stock symbol or ticker of Telix Pharmaceuticals Limited is TLX.XA.
How many shares does Telix Pharmaceuticals Limited have in circulation?
The max supply of Telix Pharmaceuticals Limited shares is 0.
What is Telix Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Telix Pharmaceuticals Limited PE Ratio is now.
What was Telix Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Telix Pharmaceuticals Limited EPS is -0.285 AUD over the trailing 12 months.